Search research articles
Contact Us
Filters
Showing results (51-60 of 87) with videos related to
Page
of 9
Sort By:
Revue Des Maladies Respiratoires
|
March 8, 2014
[Management of the cardiovascular complications of treatment in thoracic oncology]
S Ederhy, A Hollebecque, N Haddour, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 26, 2010
Poor prognosis nonseminomatous germ-cell tumours (NSGCTs): should chemotherapy doses be reduced at first cycle to prevent acute respiratory distress syndrome in patients with multiple lung metastases?
C Massard, A Plantade, M Gross-Goupil, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
April 12, 2013
Antitumour activity of abiraterone acetate against metastatic castration-resistant prostate cancer progressing after docetaxel and enzalutamide (MDV3100)
Y Loriot, D Bianchini, E Ileana, et al.
British Journal of Cancer
|
May 18, 2026
Clinico-molecular predictors of durable response to immune checkpoint inhibitors (ICI) in metastatic cervical cancer (mCC)
S Barraud, C Roussel-Simonin, P Pautier, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
November 29, 2007
Treatment outcome and survival in participants of phase I oncology trials carried out from 2003 to 2006 at Institut Gustave Roussy
A Italiano, C Massard, R Bahleda, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
May 23, 2019
Long lasting major response to pembrolizumab in a thoracic malignant rhabdoid-like SMARCA4-deficient tumor
C Henon, J-Y Blay, C Massard, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 26, 2010
Urinary N-telopeptide (uNTx) is an independent prognostic factor for overall survival in patients with bone metastases from castration-resistant prostate cancer
S Rajpar, C Massard, A Laplanche, et al.
Investigational New Drugs
|
January 5, 2012
Phase I dose-escalating study of ES-285 given as a three-hour intravenous infusion every three weeks in patients with advanced malignant solid tumors
C Massard, R Salazar, J P Armand, et al.
European Journal of Cancer (Oxford, England : 1990)
|
June 23, 2009
Phase 1 dose-escalation study of oral tyrosine kinase inhibitor masitinib in advanced and/or metastatic solid cancers
J C Soria, C Massard, N Magné, et al.
Lung Cancer (Amsterdam, Netherlands)
|
July 11, 2015
Antitumor activity in advanced cancer patients with thymic malignancies enrolled in early clinical drug development programs (Phase I trials) at Gustave Roussy
M Kossai, B Duchemann, C Boutros, et al.
Page
of 9
Search research articles
Search
Showing results (51-60 of 87) with videos related to
Sort By:
Page
of 9
Revue Des Maladies Respiratoires
|
March 8, 2014
[Management of the cardiovascular complications of treatment in thoracic oncology]
S Ederhy, A Hollebecque, N Haddour, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 26, 2010
Poor prognosis nonseminomatous germ-cell tumours (NSGCTs): should chemotherapy doses be reduced at first cycle to prevent acute respiratory distress syndrome in patients with multiple lung metastases?
C Massard, A Plantade, M Gross-Goupil, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
April 12, 2013
Antitumour activity of abiraterone acetate against metastatic castration-resistant prostate cancer progressing after docetaxel and enzalutamide (MDV3100)
Y Loriot, D Bianchini, E Ileana, et al.
British Journal of Cancer
|
May 18, 2026
Clinico-molecular predictors of durable response to immune checkpoint inhibitors (ICI) in metastatic cervical cancer (mCC)
S Barraud, C Roussel-Simonin, P Pautier, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
November 29, 2007
Treatment outcome and survival in participants of phase I oncology trials carried out from 2003 to 2006 at Institut Gustave Roussy
A Italiano, C Massard, R Bahleda, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
May 23, 2019
Long lasting major response to pembrolizumab in a thoracic malignant rhabdoid-like SMARCA4-deficient tumor
C Henon, J-Y Blay, C Massard, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 26, 2010
Urinary N-telopeptide (uNTx) is an independent prognostic factor for overall survival in patients with bone metastases from castration-resistant prostate cancer
S Rajpar, C Massard, A Laplanche, et al.
Investigational New Drugs
|
January 5, 2012
Phase I dose-escalating study of ES-285 given as a three-hour intravenous infusion every three weeks in patients with advanced malignant solid tumors
C Massard, R Salazar, J P Armand, et al.
European Journal of Cancer (Oxford, England : 1990)
|
June 23, 2009
Phase 1 dose-escalation study of oral tyrosine kinase inhibitor masitinib in advanced and/or metastatic solid cancers
J C Soria, C Massard, N Magné, et al.
Lung Cancer (Amsterdam, Netherlands)
|
July 11, 2015
Antitumor activity in advanced cancer patients with thymic malignancies enrolled in early clinical drug development programs (Phase I trials) at Gustave Roussy
M Kossai, B Duchemann, C Boutros, et al.
Page
of 9